Gains in technology stocks kept Nasdaq futures afloat on Tuesday, while futures tracking the Dow and the S&P 500 were pressured by worries of higher inflation and its impact on third-quarter earnings starting this week.
At 8:00 a.m. ET, Dow e-minis were up 6 points, or 0.02%, S&P 500 e-minis were up 3 points, or 0.07%, and Nasdaq 100 e-minis were up 37 points, or 0.25%.
Mega-caps growth names including Microsoft Corp, Facebook Inc, Amazon.com Inc, Google-parent Alphabet and Tesla inched higher in premarket trading.
Oil firms including Exxon Mobil and Chevron Corp gained 0.2% and 0.4%, respectively, as Brent crude hit a near-three year high on energy crunch fears.
Higher oil prices and supply chain disruptions have set off alarm bells for businesses and consumers ahead of the third-quarter reporting season that kicks off on Wednesday with JPMorgan Chase & Co's results.
Investors also looked ahead at the release of minutes from the Federal Reserve's meeting on Wednesday for clues on taper timeline, while inflation and retail sales data will be scrutinized to gauge the pace of economic recovery.
Stocks making the biggest moves in the premarket:
GlaxoSmithKline(GSK) – The drugmaker’s U.S.-listed shares jumped 2.6% in the premarket following a Bloomberg report that the company’s $54 billion consumer products unit is attracting buyout interest from private-equity firms. Glaxo would only say it is “far advanced” with plans to separate the consumer business.
CureVac(CVAC) – The drugmaker’s shares tumbled 13.4% in the premarket after the company said it would discontinue the development of its most advanced Covid-19 vaccine candidate. The decision came after the European Medicines Agency told the company it would not fast-track the approval process.
Airbnb(ABNB) – Cowen upgraded Airbnb to “outperform” from “market perform,” saying the Street is underestimating 2022 bookings growth and that the increase in alternative lodging will be a permanent part of the travel landscape. Airbnb shares gained 2.5% in the premarket.
Signet Jewelers(SIG) – The jewelry retailer announced the acquisition of rival Diamonds Direct for $490 million in cash, and said the deal would add immediately to earnings. Signet rallied 3.6% in premarket action.
Nike(NKE) – Nike rose 1.4% in premarket trading after Goldman Sachs initiated coverage with a “buy” rating, citing a healthy industry backdrop as well as strong growth initiatives by the athletic footwear and apparel maker.
Fastenal(FAST) – The industrial products maker matched estimates with quarterly earnings of 42 cents per share, with revenue essentially in line with forecasts. Fastenal said it continued to experience inflation related to materials and transportation costs, and its shares fell 1% in the premarket.
Southwest Airlines(LUV) – Southwest Airlines said it is hoping to normalize its schedule by Wednesday, after canceling 28% of its flights this past weekend and 10% on Monday. Southwest has cited bad weather in Florida and staffing issues for the higher level of cancellations.
American Airlines(AAL) – Shares of American Airlines Group Inc. rose 1.4% in premarket trading Tuesday, after the air carrier provided an update of its third-quarter financial outlook, which was mostly in line with previous estimates.
MGM Resorts(MGM) – MGM Resorts was upgraded to “outperform” from “neutral” at Credit Suisse, which set a price target for the resort operator’s stock at $33 per share. Credit Suisse feels MGM has not been given enough credit by the market for its ongoing transformation. MGM rallied 2.4% in premarket trading.
Tesla(TSLA) – Tesla sold just over 56,000 vehicles made in China during September, the largest monthly total since it started production in Shanghai two years ago. Tesla rose 1% in premarket trading.
Square(SQ) – Square was upgraded to “overweight” from “neutral” at Atlantic Equities, which cites valuation, strong growth prospects and a disruptive business model. The payment service’s stock rose 1.7% in the premarket.
Moderna(MRNA) – Moderna added 1.2% in premarket trading, ahead of Thursday's Food and Drug Administration panel meeting on the company's application for approval of booster shots utilizing its Covid-19 vaccine. Briefing documents are scheduled to be posted this morning, shedding some light on the prospects for approval.
精彩评论